BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

381 related articles for article (PubMed ID: 15528684)

  • 1. Prevalence and molecular analysis of macrolide and fluoroquinolone resistance among isolates of Streptococcus pneumoniae collected during the 2000-2001 PROTEKT US Study.
    Brown SD; Farrell DJ; Morrissey I
    J Clin Microbiol; 2004 Nov; 42(11):4980-7. PubMed ID: 15528684
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Distribution across the USA of macrolide resistance and macrolide resistance mechanisms among Streptococcus pneumoniae isolates collected from patients with respiratory tract infections: PROTEKT US 2001-2002.
    Farrell DJ; Jenkins SG
    J Antimicrob Chemother; 2004 Aug; 54 Suppl 1():i17-22. PubMed ID: 15265832
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevalence, characteristics, and molecular epidemiology of macrolide and fluoroquinolone resistance in clinical isolates of Streptococcus pneumoniae at five tertiary-care hospitals in Korea.
    Shin JH; Jung HJ; Kim HR; Jeong J; Jeong SH; Kim S; Lee EY; Lee JN; Chang CL
    Antimicrob Agents Chemother; 2007 Jul; 51(7):2625-7. PubMed ID: 17502407
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanisms, molecular and sero-epidemiology of antimicrobial resistance in bacterial respiratory pathogens isolated from Japanese children.
    Sunakawa K; Farrell DJ
    Ann Clin Microbiol Antimicrob; 2007 Aug; 6():7. PubMed ID: 17697316
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trends in antibacterial resistance among Streptococcus pneumoniae isolated in the USA: update from PROTEKT US Years 1-4.
    Jenkins SG; Brown SD; Farrell DJ
    Ann Clin Microbiol Antimicrob; 2008 Jan; 7():1. PubMed ID: 18190701
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibacterial resistance patterns in Streptococcus pneumoniae isolated from elderly patients: PROTEKT years 1-5 (1999-2004).
    Cantón R; Unal S; Farrell DJ
    Int J Antimicrob Agents; 2007 Dec; 30(6):546-50. PubMed ID: 17931834
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevalence and antibacterial susceptibility of mef(A)-positive macrolide-resistant Streptococcus pneumoniae over 4 years (2000 to 2004) of the PROTEKT US Study.
    Farrell DJ; File TM; Jenkins SG
    J Clin Microbiol; 2007 Feb; 45(2):290-3. PubMed ID: 17093012
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Levofloxacin-resistant invasive Streptococcus pneumoniae in the United States: evidence for clonal spread and the impact of conjugate pneumococcal vaccine.
    Pletz MW; McGee L; Jorgensen J; Beall B; Facklam RR; Whitney CG; Klugman KP
    Antimicrob Agents Chemother; 2004 Sep; 48(9):3491-7. PubMed ID: 15328116
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Emergence and spread of Streptococcus pneumoniae with erm(B) and mef(A) resistance.
    Farrell DJ; Jenkins SG; Brown SD; Patel M; Lavin BS; Klugman KP
    Emerg Infect Dis; 2005 Jun; 11(6):851-8. PubMed ID: 15963279
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Distribution and antibacterial susceptibility of macrolide resistance genotypes in Streptococcus pneumoniae: PROTEKT Year 5 (2003-2004).
    Farrell DJ; Couturier C; Hryniewicz W
    Int J Antimicrob Agents; 2008 Mar; 31(3):245-9. PubMed ID: 18178388
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Macrolide resistance mechanisms among Streptococcus pneumoniae isolated over 6 years of Canadian Respiratory Organism Susceptibility Study (CROSS) (1998 2004).
    Wierzbowski AK; Nichol K; Laing N; Hisanaga T; Nikulin A; Karlowsky JA; Hoban DJ; Zhanel GG
    J Antimicrob Chemother; 2007 Oct; 60(4):733-40. PubMed ID: 17673477
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Worldwide incidence, molecular epidemiology and mutations implicated in fluoroquinolone-resistant Streptococcus pneumoniae: data from the global PROTEKT surveillance programme.
    Canton R; Morosini M; Enright MC; Morrissey I
    J Antimicrob Chemother; 2003 Dec; 52(6):944-52. PubMed ID: 14585861
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Macrolide resistance determinants in erythromycin-resistant Streptococcus pneumoniae in Turkey.
    Gulay Z; Ozbek OA; Bicmen M; Gur D
    Jpn J Infect Dis; 2008 Nov; 61(6):490-3. PubMed ID: 19050364
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular characterization of macrolide resistance mechanisms among Streptococcus pneumoniae and Streptococcus pyogenes isolated from the PROTEKT 1999-2000 study.
    Farrell DJ; Morrissey I; Bakker S; Felmingham D
    J Antimicrob Chemother; 2002 Sep; 50 Suppl S1():39-47. PubMed ID: 12239227
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibacterial resistance of community-acquired respiratory tract pathogens recovered from patients in Latin America: results from the PROTEKT surveillance study (1999-2000).
    Mendes C; Marin ME; Quiñones F; Sifuentes-Osornio J; Siller CC; Castanheira M; Zoccoli CM; López H; Súcari A; Rossi F; Angulo GB; Segura AJ; Starling C; Mimica I; Felmingham D
    Braz J Infect Dis; 2003 Feb; 7(1):44-61. PubMed ID: 12807691
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antimicrobial susceptibility of Streptococcus pneumoniae, Streptococcus pyogenes and Haemophilus influenzae collected from patients across the USA, in 2001-2002, as part of the PROTEKT US study.
    Brown SD; Rybak MJ
    J Antimicrob Chemother; 2004 Aug; 54 Suppl 1():i7-15. PubMed ID: 15265831
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The molecular epidemiology of Streptococcus pneumoniae with quinolone resistance mutations.
    Richter SS; Heilmann KP; Beekmann SE; Miller NJ; Rice CL; Doern GV
    Clin Infect Dis; 2005 Jan; 40(2):225-35. PubMed ID: 15655739
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic options among broad-spectrum beta-lactams for infections caused by levofloxacin-nonsusceptible Streptococcus pneumoniae.
    Jones RN; Fritsche TR; Sader HS
    Diagn Microbiol Infect Dis; 2005 Jun; 52(2):129-33. PubMed ID: 15964501
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trends in anti-bacterial resistance among Streptococcus pneumoniae isolated in the USA, 2000-2003: PROTEKT US years 1-3.
    Jenkins SG; Farrell DJ; Patel M; Lavin BS
    J Infect; 2005 Dec; 51(5):355-63. PubMed ID: 15950288
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antimicrobial resistance among isolates of respiratory tract infection pathogens from the southern United States: data from the PROTEKT US surveillance program 2000/2001.
    Waites K; Brown S
    South Med J; 2003 Oct; 96(10):974-85. PubMed ID: 14570341
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.